Mutating HIV Virus Making It Difficult To Develop Vaccine

THE ever-changing genetic makeup and rapid mutation of the HIV virus has to a larger extent slowed down progress towards successfully developing an effective HIV vaccine, a top Zimbabwean expert has said. By Michael Gwarisa The revelations also follow the recent abandonment of the Imbokodo HIV vaccine or HVTN 705/HPX2008 efficacy studies after revelations that the vaccine was not granting enough protection against infection. In an interview with HealthTimes, Dr Portia Hunidzarira, the Principal Researcher for the Imbokodo vaccine studies said the HIV virus mutates at a faster rate and…

Read More

HIV Vaccine Trials Discontinued After It Fails To Prevent HIV Infection

THE HVTN 705/HPX2008 or Imbokodo study, which began in 2017 to test whether the Imbokodo vaccine regimen could prevent women in Sub-Saharfan Africa from getting HIV has been discontinued following indications that the vaccine did not provide sufficient protection against infection. By Michael Gwarisa In a statement, Johnson & Johnson said data showed the investigational HIV  vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub–Saharan Africa at high risk of acquiring HIV even though the investigational vaccine was found to have…

Read More

Researchers Not Giving Up On Imbokodo HIV Vaccine Study

PERSISTENT researchers feel the halted HTVN 702 study on the efficacy of an HIV vaccine will not affect the Imbokodo Vaccine Trial study launched in 2017. By Kudakwashe Pembere HVTN  702 study was stopped following an interim analysis conducted on 23 January 2020 by an independent Data and Safety Monitoring Board (DSMB) that reviews all data regularly to ensure the safety of participants and determine if the study should continue. The DSMB assessment concluded that the experimental vaccine regimen used in the trial did not prevent HIV infection. The vaccine…

Read More